SILVER SPRING
Insulin aspart-fsan biosimilar Garzulys cleared
- Sponsor
- Meitheal Pharmaceuticals, Inc.
- Drug
- Garzulys · insulin aspart-fsan
- Indication
- Glycemic control in diabetes
FDA approves Garzulys, a biosimilar to NovoLog (insulin aspart), for glycemic control in diabetes.
What this means
Garzulys is a biosimilar version of insulin aspart, a fast-acting insulin used to control blood sugar in people with diabetes. The FDA has cleared it for marketing, meaning it can now be prescribed. This approval provides patients and doctors with another treatment option that may help increase access to this essential medication.